Literature DB >> 19833365

Glaucoma and systemic diseases.

Sarwat Salim1, M Bruce Shields.   

Abstract

Glaucoma management may be extremely challenging, especially in elderly patients who have a variety of systemic diseases and take multiple medications. We obtained a comprehensive medical history in patients with primary open-angle glaucoma to determine which systemic diseases are most prevalent and which systemic medications are most commonly used. We have also reviewed the literature that addresses how these concomitant diseases and medical treatments influence the management of glaucoma. Knowledge of systemic diseases and potential drug interactions, especially between various systemic and glaucoma medications, is important for the safe management of glaucoma patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19833365     DOI: 10.1016/j.survophthal.2009.03.006

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  8 in total

1.  Background polygenic risk modulates the association between glaucoma and cardiopulmonary diseases and measures: an analysis from the UK Biobank.

Authors:  Janey Wiggs; Nazlee Zebardast; Ajay Kolli; Sayuri Sekimitsu; Jiali Wang; Ayellet Segre; David Friedman; Tobias Elze; Louis R Pasquale
Journal:  Br J Ophthalmol       Date:  2022-03-31       Impact factor: 5.908

2.  Prevalence of diabetes mellitus and hypertension among Indian glaucoma patients and evaluation of systemic therapy.

Authors:  Abhishek Dave; Shveta Jindal Bali; Reetika Sharma; Aruj K Khurana; Raghav Gupta; Tanuj Dada
Journal:  Int Ophthalmol       Date:  2013-02-14       Impact factor: 2.031

3.  Comparing the efficacy of the monocular trial treatment paradigm with multiple measurements of intraocular pressure before and after treatment initiation in primary open-angle glaucoma.

Authors:  Rohit Krishna; Peter W Debry; Corey W Waldman; Peter Koulen
Journal:  Clin Ophthalmol       Date:  2012-03-28

4.  Outcomes Following Implantation of Two Second-Generation Trabecular Micro-Bypass Stents in Patients with Open-Angle Glaucoma on One Medication: 18-Month Follow-Up.

Authors:  Richard Lindstrom; Richard Lewis; Dana M Hornbeak; Lilit Voskanyan; Jane Ellen Giamporcaro; John Hovanesian; Steven Sarkisian
Journal:  Adv Ther       Date:  2016-10-13       Impact factor: 3.845

5.  Outcomes of combined trabecular micro-bypass and phacoemulsification in a predominantly Hispanic patient population.

Authors:  Mark J Gallardo; Richard A Supnet; Jane Ellen Giamporcaro; Dana M Hornbeak
Journal:  Clin Ophthalmol       Date:  2016-10-11

6.  Implantation of two second-generation trabecular micro-bypass stents and topical travoprost in open-angle glaucoma not controlled on two preoperative medications: 18-month follow-up.

Authors:  John Berdahl; Lilit Voskanyan; Jonathan S Myers; Dana M Hornbeak; Jane Ellen Giamporcaro; L Jay Katz; Thomas W Samuelson
Journal:  Clin Exp Ophthalmol       Date:  2017-06-02       Impact factor: 4.207

7.  Epidemiology and clinical characteristics of patients with glaucoma: An analysis of hospital data between 2003 and 2012.

Authors:  Yang Zhao; Jia-Li Fu; Yu-Li Li; Ping Li; Feng-Lan Lou
Journal:  Indian J Ophthalmol       Date:  2015-11       Impact factor: 1.848

8.  Newly Diagnosed Primary Open-Angle Glaucoma Randomized to 2 Trabecular Bypass Stents or Prostaglandin: Outcomes Through 36 Months.

Authors:  Steven D Vold; Lilit Voskanyan; Manfred Tetz; Gerd Auffarth; Imran Masood; Leon Au; Iqbal Ike K Ahmed; Hady Saheb
Journal:  Ophthalmol Ther       Date:  2016-09-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.